The Korea Exchange's securities market headquarters noted on the 21st that it made a qualified decision on the preliminary review for the partitioning re-listing of Samsung Biologics.
Samsung Biologics plans to spin off its subsidiary management and new investment institutional sector into Samsung Bioepis Holdings (tentative) for re-listing. The newly established Samsung Bioepis Holdings as a pure holding corporation will incorporate the biopharmaceutical company Samsung Bioepis as a wholly-owned subsidiary in the future, and is expected to establish a new subsidiary in November.
According to industry sources, existing shareholders of Samsung Biologics will receive shares of Samsung Biologics and Samsung Bioepis Holdings at a ratio of 0.6503913 to 0.3496087.